- Title
- Cannabidiol - Help and hype in targeting mucosal diseases
- Creator
- Moniruzzaman, Md; Janjua, Taskeen Iqbal; Martin, Jennifer H.; Begun, Jakob; Popat, Amirali
- Relation
- NHMRC.GNT1135054 http://purl.org/au-research/grants/nhmrc/1135054
- Relation
- Journal of Controlled Release Vol. 365, Issue January 2024, p. 530-543
- Publisher Link
- http://dx.doi.org/10.1016/j.jconrel.2023.11.010
- Publisher
- Elsevier
- Resource Type
- journal article
- Date
- 2024
- Description
- Cannabidiol (CBD) is one of the most commonly utilised phytocannabinoids due to its non-psychoactive and multiple potential therapeutic properties and its non-selective pharmacology. Recent studies have demonstrated efficacy of CBD in some types of drug resistant epilepsies in combination with other therapies; comparative efficacy to other agents or placebo has been hoped for anxiety, chronic pain, and inflammatory disorders based on animal data. Although CBD products are generally treated as a restricted substance, these are being eased, partially in response to significant growth in CBD product usage and increased production but more due to emerging evidence about its safety and pharmacological properties. Currently, only one CBD product (Epidiolex®) has been approved by the Australian Therapeutic Goods Administration and US Food and Drug Administration. CBD has demonstrated promise in alleviating gut and lung diseases in vitro; however, its physicochemical properties pose a significant barrier to achieving pharmacological effects in in vivo and clinical trials. Improving CBD formulations and delivery methods using technologies including self-emulsifying emulsion, nano and micro particles could overcome these shortfalls and improve its efficacy. This review focuses on the therapeutic potential of CBD in gastrointestinal and lung diseases from the available in vitro, in vivo, and clinical research. We report on identified research gaps and obstacles in the development of CBD-based therapeutics, including novel delivery methods.
- Subject
- cannabidiol; inflammatory bowel diseases; colorectal cancer; COVID-19; lung cancer; nanoparticle; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1496201
- Identifier
- uon:54160
- Identifier
- ISSN:0168-3659
- Rights
- © 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
- Language
- eng
- Full Text
- Reviewed
- Hits: 3013
- Visitors: 3052
- Downloads: 61
Collections
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Publisher version (open access) | 3 MB | Adobe Acrobat PDF | View Details Download |